SQZB (SQZ Biotechnologies Co) EBIT: $-60.65 Mil (TTM As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SQZB SQZ Biotechnologies Co SQZB
12 GF Score
Price $0.02
View Full Analysis

What is SQZ Biotechnologies Co EBIT?

SQZ Biotechnologies Co SQZB 12 EBIT is $-60.65 Mil as of Sep. 2023. GuruFocus rates SQZB with a GF Score™ of 12/100.

SQZ Biotechnologies Co's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was $-16.12 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was $-60.65 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. SQZ Biotechnologies Co's annualized ROC % for the quarter that ended in Sep. 2023 was -257.96%. SQZ Biotechnologies Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -325.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. SQZ Biotechnologies Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -8,566.53%.

SQZ Biotechnologies Co  (OTCPK:SQZB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

SQZ Biotechnologies Co's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

ROC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=-64.472 * ( 1 - 0% )/( (29.82 + 20.166)/ 2 )
=-64.472/24.993
=-257.96 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=54.148 - 6.554 - ( 24.71 - max(0, 9.911 - 27.685+24.71))
=29.82

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=29.788 - 6.367 - ( 10.193 - max(0, 8.832 - 12.087+10.193))
=20.166

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

SQZ Biotechnologies Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Sep. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-64.472/( ( (24.158 + max(-4.277, 0)) + (15.396 + max(-4.541, 0)) )/ 2 )
=-64.472/( ( 24.158 + 15.396 )/ 2 )
=-64.472/19.777
=-325.99 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 2.975) - (6.554 + 0.5 + 0.198)
=-4.277

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.894) - (6.367 + 0 + 0.068000000000001)
=-4.541

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

SQZ Biotechnologies Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2023 )
=-60.651/0.708
=-8,566.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SQZ Biotechnologies Co EBIT Related Terms

SQZ Biotechnologies Co EBIT Historical Data

* Premium members only.

The historical data trend for SQZ Biotechnologies Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SQZ Biotechnologies Co EBIT Chart

SQZ Biotechnologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
EBIT
-19.19 -34.27 -51.06 -68.77 -75.83

SQZ Biotechnologies Co Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.10 -9.17 -18.26 -17.11 -16.12

SQZB vs AGTX, ISCO, VYNT: EBIT Comparison

For the Biotechnology subindustry, SQZ Biotechnologies Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SQZ Biotechnologies Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's EV-to-EBIT falls into.


SQZB
12GF Score
SQZ Biotechnologies Co SQZB
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SQZ Biotechnologies Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.65 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-60.65 Mil mean?
SQZ Biotechnologies Co (SQZB) has a EBIT of $-60.65 Mil as of Sep. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SQZ Biotechnologies Co.
Is SQZ Biotechnologies Co's EBIT too high?
SQZ Biotechnologies Co's current EBIT is $-60.65 Mil. Overall, SQZ Biotechnologies Co has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SQZ Biotechnologies Co's EBIT compare to AGTX and ISCO?
SQZ Biotechnologies Co's EBIT of $-60.65 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on SQZ Biotechnologies Co. SQZ Biotechnologies Co's current EBIT is $-60.65 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SQZ Biotechnologies Co stock overvalued right now?
SQZ Biotechnologies Co (SQZB) has a current EBIT of $-60.65 Mil. The current EBIT is $-60.65 Mil. SQZ Biotechnologies Co's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For SQZ Biotechnologies Co (SQZB), the current EBIT is $-60.65 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SQZ Biotechnologies Co Business Description

Address 200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472
SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.
12GF Score

Get the complete analysis for SQZB

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.02
Price